UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 418

Sortiert nach

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters

Molecules (Basel, Switzerland), 2020-06, Vol.25 (11), p.2718

2020

Volltextzugriff (PDF)

Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome

Pharmacotherapy, 2024-01, Vol.44 (1), p.22-27

2024

Volltextzugriff (PDF)

Genome-wide pQTL analysis of protein expression regulatory networks in the human liver

BMC biology, 2020-08, Vol.18 (1), p.97-97, Article 97

2020

Volltextzugriff (PDF)

Identification of regulatory variants of carboxylesterase 1 (CES1): A proof‐of‐concept study for the application of the Allele‐Specific Protein Expression (ASPE) assay in identifying cis‐acting regulatory genetic polymorphisms

Proteomics (Weinheim), 2023-01, Vol.23 (1), p.e2200176-n/a

2023

Volltextzugriff (PDF)

FRACPRED‐2D‐PRM: A Fraction Prediction Algorithm‐Assisted 2D Liquid Chromatography‐Based Parallel Reaction Monitoring‐Mass Spectrometry Approach for Measuring Low‐Abundance Proteins in Human Plasma

Proteomics (Weinheim), 2020-12, Vol.20 (24), p.e2000175-n/a

2020

Volltextzugriff (PDF)

Functional Study of Carboxylesterase 1 Protein Isoforms

Proteomics (Weinheim), 2019-02, Vol.19 (4), p.e1800288-n/a

2019

Volltextzugriff (PDF)

Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes

Drug metabolism and pharmacokinetics, 2018-04, Vol.33 (2), p.133-140

2018

Volltextzugriff (PDF)

Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender

Biochemical pharmacology, 2016-11, Vol.119, p.76-84

2016

Volltextzugriff (PDF)

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators

Drug metabolism and disposition, 2020-03, Vol.48 (3), p.230-244

2020

Volltextzugriff (PDF)

Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof‐of‐Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism

Clinical pharmacology and therapeutics, 2022-04, Vol.111 (4), p.878-885

2022

Volltextzugriff (PDF)

Tissue‐ and cell‐expression of druggable host proteins provide insights into repurposing drugs for COVID‐19

Clinical and translational science, 2022-12, Vol.15 (12), p.2796-2811

2022

Volltextzugriff (PDF)

Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability

Drug metabolism and disposition, 2019-11, Vol.47 (11), p.1314-1324

2019

Volltextzugriff (PDF)

Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI)

Rapid communications in mass spectrometry, 2016-03, Vol.30 (5), p.553-561

2016

Volltextzugriff (PDF)

Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method

Journal of proteome research, 2018-10, Vol.17 (10), p.3606-3612

2018

Volltextzugriff (PDF)

A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms

Drug metabolism and disposition, 2017-11, Vol.45 (11), p.1149-1155

2017

Volltextzugriff (PDF)

Effect of CES1 genetic variation on enalapril steady‐state pharmacokinetics and pharmacodynamics in healthy subjects

British journal of clinical pharmacology, 2021-12, Vol.87 (12), p.4691-4700

2021

Volltextzugriff (PDF)

Carboxylesterase 1-Mediated Drug–Drug Interactions between Clopidogrel and Simvastatin

Biological and Pharmaceutical Bulletin, 2015/02/01, Vol.38(2), pp.292-297

2015

Volltextzugriff (PDF)

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms

Basic & clinical pharmacology & toxicology, 2016-12, Vol.119 (6), p.555-561

2016

Volltextzugriff (PDF)

An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study

Drug metabolism and disposition, 2013-09, Vol.41 (9), p.1679

2013

Volltextzugriff (PDF)

Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection

Pharmaceutics, 2021-10, Vol.13 (10), p.1656

2021

Volltextzugriff (PDF)

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants

Drug metabolism and disposition, 2009-02, Vol.37 (2), p.264

2009

Volltextzugriff (PDF)

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers

Clinical and translational science, 2021-07, Vol.14 (4), p.1380-1389

2021

Volltextzugriff (PDF)

Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study

Biochemical pharmacology, 2017-05, Vol.131, p.89-97

2017

Volltextzugriff (PDF)

Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis

American journal of human genetics, 2008-06, Vol.82 (6), p.1241-1248

2008

Volltextzugriff (PDF)

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

Frontiers in pharmacology, 2022-11, Vol.13, p.1007113-1007113

2022

Volltextzugriff (PDF)

1 – 25 von 418

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(361)
Mit Volltextzugriff
(368)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters

Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome

Genome-wide pQTL analysis of protein expression regulatory networks in the human liver

Identification of regulatory variants of carboxylesterase 1 (CES1): A proof‐of‐concept study for the application of the Allele‐Specific Protein Expression (ASPE) assay in identifying cis‐acting regulatory genetic polymorphisms

FRACPRED‐2D‐PRM: A Fraction Prediction Algorithm‐Assisted 2D Liquid Chromatography‐Based Parallel Reaction Monitoring‐Mass Spectrometry Approach for Measuring Low‐Abundance Proteins in Human Plasma

Functional Study of Carboxylesterase 1 Protein Isoforms

Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes

Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators

Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof‐of‐Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism

Tissue‐ and cell‐expression of druggable host proteins provide insights into repurposing drugs for COVID‐19

Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability

Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI)

Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method

A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms

Effect of CES1 genetic variation on enalapril steady‐state pharmacokinetics and pharmacodynamics in healthy subjects

Carboxylesterase 1-Mediated Drug–Drug Interactions between Clopidogrel and Simvastatin

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms

An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study

Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers

Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study

Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

Suchergebnisse filtern